Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Portfolio Pulse from Lisa Levin
Several stocks experienced significant price movements in Wednesday's mid-day session. Eiger BioPharmaceuticals shares dropped by 52.5% after the company decided to discontinue a Phase 3 study. Avalo Therapeutics shares surged by 68% after receiving a notice from Nasdaq. Rocket Pharmaceuticals rose by 31.8% after reaching alignment with the FDA on a global Phase 2 trial. HireRight Holdings climbed by 14.8% after planning an additional $25 million share repurchase program. REV Group surged by 9.2% after reporting better-than-expected Q3 results and raising FY23 net sales guidance.
September 13, 2023 | 6:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avalo Therapeutics shares surged by 68% after receiving a notice from Nasdaq.
The notice from Nasdaq is a positive development for Avalo Therapeutics, leading to a surge in its stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
HireRight Holdings climbed by 14.8% after planning an additional $25 million share repurchase program.
The plan for an additional $25 million share repurchase program is a positive development for HireRight Holdings, leading to a climb in its stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
Rocket Pharmaceuticals rose by 31.8% after reaching alignment with the FDA on a global Phase 2 trial.
The alignment with the FDA on a global Phase 2 trial is a positive development for Rocket Pharmaceuticals, leading to a rise in its stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
REV Group surged by 9.2% after reporting better-than-expected Q3 results and raising FY23 net sales guidance.
The better-than-expected Q3 results and raised FY23 net sales guidance are positive developments for REV Group, leading to a surge in its stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
NEGATIVE IMPACT
Eiger BioPharmaceuticals shares dropped by 52.5% after the company decided to discontinue a Phase 3 study.
The decision to discontinue a Phase 3 study is a significant setback for Eiger BioPharmaceuticals, leading to a sharp drop in its stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100